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Abstract
Background: Carbapenemase-producing Enterobacteriaceae (CPE) are difficult to identify among carbapenem non-
susceptible Enterobacteriaceae (NSE). We designed phenotypic strategies giving priority to high sensitivity for
screening putative CPE before further testing.
Methods: Presence of carbapenemase-encoding genes in ertapenem NSE (MIC > 0.5 mg/l) consecutively isolated in
80 French laboratories between November 2011 and April 2012 was determined by the Check-MDR-CT103 array
method. Using the Mueller-Hinton (MH) disk diffusion method, clinical diameter breakpoints of carbapenems other
than ertapenem, piperazicillin+tazobactam, ticarcillin+clavulanate and cefepime as well as diameter cut-offs for
these antibiotics and temocillin were evaluated alone or combined to determine their performances (sensitivity,
specificity, positive and negative likelihood ratios) for identifying putative CPE among these ertapenem-NSE isolates.
To increase the screening specificity, these antibiotics were also tested on cloxacillin-containing MH when
carbapenem NSE isolates belonged to species producing chromosomal cephalosporinase (AmpC) but Escherichia
coli.
Results: Out of the 349 ertapenem NSE, 52 (14.9%) were CPE, including 39 producing OXA-48 group
carbapenemase, eight KPC and five MBL. A screening strategy based on the following diameter cut offs, ticarcillin
+clavulanate <15 mm, temocillin <15 mm, meropenem or imipenem <22 mm, and cefepime <26 mm, showed
100% sensitivity and 68.1% specificity with the better likelihood ratios combination. The specificity increased when a
diameter cut-off <32 mm for imipenem (76.1%) or meropenem (78.8%) further tested on cloxacillin-containing MH
was added to the previous strategy for AmpC-producing isolates.
Conclusion: The proposed strategies that allowed for increasing the likelihood of CPE among ertapenem-NSE
isolates should be considered as a surrogate for carbapenemase production before further CPE confirmatory testing.
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Background
Preventing the spread of carbapenemase-producing En-
terobacteriaceae (CPE) is a priority because it may lead
to therapeutic dead end [1]. The control strategies are
based on better antibiotic use and decrease in cross-
transmission. Thus, rapid detection of CPE in the la-
boratory is of paramount importance [2]. However, this
detection is complex because carbapenemases display
various hydrolytic activities with regard to β-lactams and
mechanisms other than carbapenemase production,
namely overproduction of AmpC β-lactamase and/or
production of ESBL in isolates displaying reduced outer
membrane permeability, are involved in resistance to
carbapenems. In addition, appropriate studies have
shown that the incidence of CPE is very low in some
countries and that the other resistance mechanisms are
the most frequent in carbapenem non-susceptible
Enterobacteriaceae (NSE) [3–5]. Therefore, looking for
CPE among all carbapenem NS isolates is difficult, and
the routine clinical laboratory is in need of simple tools
allowing for the rapid suspicion of CPE among carba-
penem NSE isolates before further testing by more spe-
cific tests.
Recent tests designed to specifically detect carbape-
nemase production by real-time PCR assays [6] or
carbapenem hydrolysis [7, 8] have been developed [9].
Nevertheless, these tests are not yet available in any
microbiological laboratory or some may be costly if
applied on all carbapenem NSE in a context of low
CPE incidence. Thus, the objective is to decrease the
number of carbapenem NSE submitted to such spe-
cific tests. For this purpose, a few teams sought to
delineate laboratory screening strategies based on
simple and widely available tests to identify isolates
with high likelihood of being CPE among carbapenem
NSE [10–15]. However, the effectiveness of these
screening strategies has mostly been tested against
biased samples, i.e. samples among which CPE were
by far over-represented as compared to the current
CPE prevalence [11, 12].
As we reported a low proportion (circa 10%) of CPE
among non-selected carbapenem NSE in France in
2011–2012 [5], the French committee on antibiotic sus-
ceptibility testing (CA-SFM) affiliated to the European
committee on antimicrobial susceptibility testing
(EUCAST) raised interest in using this unbiased isolates
collection to develop a screening strategy that could be
applied in all laboratories to eliminate with certainty
carbapenemase-negative isolates among carbapenem
NSE. The aim of this article is to present the process
used to establish a comprehensive screening algorithm,





A total of 80 laboratories throughout the French terri-
tory participated on a voluntary basis in the study during
a 6-month period in 2011–2012. As referral centre, we
received 744 non-duplicate ertapenem NSE (ertapenem
MIC >0.5 mg/L: broth microdilution method according
to EUCAST recommendations) [16] consecutively col-
lected, including 392 (52.7%) Enterobacter cloacae. Be-
cause of the very low prevalence of carbapenemase in E.
cloacae at the period of the study [5], we randomly se-
lected one fifth of the isolates belonging to this species
for comprehensive analysis by using a roster ordered by
laboratory and by isolation date. Therefore, 349 non-
duplicate ertapenem NSE isolates, including 222 clinical
isolates previously reported [5] and 127 consecutive iso-
lates obtained from screening rectal swabs were studied.
Isolates were characterised (species identification, anti-
biotic susceptibility and ESBL production) in each la-
boratory and further analysed by the referral centre,
notably with regard to their bla gene content (Check-
MDR CT103 array, Check-Points, Wageningen, The
Netherlands) [5].
Antibiotic susceptibility
The following antibiotic were tested by using the agar
diffusion method following the 2011 CA-SFM recom-
mendations on Mueller-Hinton agar medium (MH, Bio-
Rad, Marne La Coquette, France) and on MH containing
250 mg/L cloxacillin (MHcloxa, bioMérieux, Marcy
l’Etoile, France): ertapenem 10 μg, imipenem 10 μg, mer-
openem 10 μg, doripenem 10 μg, ticarcillin/clavulanate
75/10 μg, piperacillin/tazobactam 75/10 μg, cefotaxime
30 μg, ceftazidime 30 μg, cefepime 30 μg, and temocillin
30 μg [17].
Imipenem and meropenem MICs were determined by
using the broth microdilution method in 96 wells-
plaques containing lyophilized antibiotics (Sensititre
MIC plates, Biocentric, Bandol, France).
Additional phenotypic test designed for carbapenemase
detection
Because previously described screening strategies [13,
15] included the use of the Rosco Diagnostica Neo-
Sensitabs KPC and MBL confirm kit (Eurobio, Les Ullis
France), each isolate of our collection was also submitted
to this test according to manufacturer’s instructions. It
consists of four tablets: tablet A containing meropenem,
tablet B containing meropenem and dipicolinic acid
[metallo-β-lactamase (MBL) inhibitor], tablet C contain-
ing meropenem and cloxacillin (AmpC inhibitor), and
tablet D containing meropenem and boronic acid (class
A carbapenemase KPC inhibitor). The inhibition zone
diameter around tablet A was compared to that of each
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of meropenem-plus-inhibitor tablets (B, C, and D). If
diameter around tablet B showed a difference >4 mm
from that around tablet A, the isolate was recorded as
demonstrating MBL activity. If diameter around tablet D
showed a difference >4 mm from that of tablet A, the
isolate was recorded as demonstrating KPC activity. If
diameters around tablets C and D both showed a differ-
ence >4 mm from that of tablet A, the isolate was re-
corded as demonstrating AmpC activity coupled with
outer membrane impermeability.
Data analysis
The main objective of the analysis was to determine
strategies based on the disk diffusion method allowing
for retaining all carbapenemase-producing isolates
(100% sensitivity, Se) and reducing the number of iso-
lates submitted to CPE confirmatory tests, i.e. with
the highest specificity. The performances, i.e. Se, spe-
cificity (Sp), positive (+) and negative (−) likelihood
ratios (LR), were computed for single or combined
screening tests with regard to their ability to separate
carbapenemase-producing isolates from those non-
producing carbapenemase.
These performances were successively evaluated with
regard to clinical breakpoints delineating NS isolates
from the susceptible (CA-SFM) ones, diameter cut-offs
and specific carbapenemase detection test (Rosco test)
previously published in strategies designed for screening
of carbapenemase-positive isolates [13–15, 18], as well
as diameter cut-offs determined in the present study by
analysing the distributions of inhibition zone diameters
displayed by our non-selected isolate collection (Add-
itional file 1: Figure S1).
We used LR because they are independent of the pre-
test probability of the event in the tested population
(prevalence rate), in contrast with positive and negative
predictive values. Moreover, by using the Fagan’s nomo-
gram, each laboratory can derive the positive and nega-
tive predictive values of any test by using the LR of the
test and the prevalence rate of the event before the test
[19]. The LR of a positive test (LR+) is the ratio of the
true-positive rate to the false-positive rate, i.e. Se/(1-Sp).
The LR of a negative test (LR-) is the ratio of the false-
negative rate to the true-negative rate, i.e. (1-Se)/Sp.
Hence, the values of the LR range from zero to infinity.
The farther the LR value is away from 1 (reference
where the test has no diagnostic value), the stronger the
interest of the test.
LR graphs derived from standard receiver operating
characteristics curves analysis were used to visually com-
pare the interest of “screening tests” (II) to a reference
test (I) [20, 21]. Non-susceptibility to imipenem as de-
fined by CA-SFM clinical breakpoint (imipenem inhib-
ition diameter size <24 mm) was chosen as reference
test because it is a widely used test in routine suscepti-
bility testing. In LR graphs, the false-positive rate (1-Sp)
of the reference (I) is plotted against its true-positive
rate (Se). The slope of a solid line connecting this de-
fined point to the point (0,0) represents the LR of a posi-
tive test, and the slope of a dashed line connecting this
point to the point (1,1) represents the LR of a negative
test (Fig. 2). Consequently, four regions are defined: re-
gion A, where the value of the screening test (II) yields
overall superior characteristics than the reference (LR+
test II > LR+ test I and LR- test II < LR- test I); region B,
where the value of the screening test (II) is superior to
test I to eliminate the production of carbapenemase (LR
+ test II < LR+ test I and LR- test II < LR- test I); region
C, where the value of test II is superior for retaining iso-
lates likely to produce of carbapenemase (LR+ test II >
LR+ test I and LR- test II > LR- test I); region D, where
the value of test II is inferior overall (LR+ test II < LR+
test I and LR- test II > LR- test I).
Statistical analysis
The McNemar’s test with exact significance probability
was used to compare Se and Sp of selected tests and
strategies.
Results
The characteristics of the 349 ertapenem-NS isolates are
shown in Table 1. A total of 52 (14.9%) isolates har-
boured carbapenemase genes, and 179 (51.3%) produced
ESBL. Carbapenemase-encoding genes were the most
frequent in Klebsiella pneumoniae (27.3%) and E. coli
(23.8%), while none of the Enterobacter spp harboured
Table 1 Number and proportion of ESBL-producing and
carbapenemase-producing Enterobacteriaceae included in the
study according to species
Species Number (%) of isolates
Total ESBL+ Carbapenemase positive
Total OXA-48 KPC MBL
Klebsiella pneumoniae 121 91 (75.2) 33 (27.3) 24 7 2
Enterobacter cloacae 89 32 (36.0) 0
Enterobacter aerogenes 46 20 (43.5) 0
Escherichia coli 42 24 (57.1) 10 (23.8) 9 1
Citrobacter freundii 18 7 (38.9) 2 (11.1) 1 1
Serratia marcescens 10 0 2 (20.0) 2
Klebsiella oxytoca 5 0 2 (40.0) 2
Proteus mirabilis 1 1 (100) 1 (100) 1
Salmonella spp 1 1 (100) 1 (100) 1
Others 16 3 (18.8) 1 (6.3) 1
Total 349 179 (51.3) 52 (14.9) 39 8 5
ESBL+ extended-spectrum β-lactamase production, OXA-48 OXA-48 group
carbapenemase, MBL metallo-beta-lactamase
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carbapenemase-encoding genes. Among the 52
carbapenemase-encoding genes, 39 (75.0%) encoded for
the OXA-48 group carbapenemase, eight (15.4%) for
KPC, and five (9.6%) for MBL. Imipenem MIC for the
52 CPE ranged from 1 mg/L to 64 mg/L, with 18
(34.6%) isolates displaying an imipenem MIC ≤ 2 mg/L.
Meropenem MIC for CPE ranged from 0.25 mg/L to
64 mg/L, with 28 (53.8%) isolates displaying a merope-
nem MIC ≤ 2 mg/L. All CPE isolates with imipenem or
meropenem MIC ≤ 2 mg/L produced OXA-48 group
carbapenemases.
Screening with a single antibiotic disk
When using the inhibition zone diameter of a single
antibiotic disk and CA-SFM clinical breakpoints, non-
susceptibility to carbapenems other than ertapenem
yielded Se ranging from 32.7 to 42.3% (Table 2) to
screen CPE among ertapenem NS isolates. Higher Se
Table 2 Sensitivity (Se, %), specificity (Sp, %), positive and negative likelihood ratios (LR+ and LR-, respectively) of screening
strategies for carbapenemase-positive isolates among 349 isolates non-susceptible to ertapenem










IMI 24 22 (42.3) 44 (14.8) 42.3 85.2 2.84 0.68
MER 22 22 (42.3) 40 (13.5) 42.3 86.5 3.12 0.67
DOR 24 17 (32.7) 22 (7.4) 32.7 92.6 4.37 0.72
TAZ 21 51 (98.1) 220 (74.1) 98.1 25.9 1.31 0.11
TCC 24 51 (98.1) 292 (98.3) 98.1 1.7 0.99 1.53
FEP 24 42 (80.8) 138 (46.5) 80.8 53.5 1.73 0.37
Cut-offs
MER 27 a 40 (76.9) 80 (27.0) 76.9 73.0 2.83 0.32
TEM 8 a 35 (67.3) 12 (4.0) 67.3 96.0 15.97 0.34
TAZ 16 b 46 (88.5) 105 (35.4) 88.5 64.7 2.48 0.19
TEM 12 b 43 (82.7) 65 (21.9) 82.7 78.1 3.73 0.23
MER 25 c 32 (61.5) 59 (19.9) 61.5 80.1 3.07 0.48
TCC 15 d 51 (98.1) 227 (76.4) 98.1 23.6 1.27 0.12
TEM 15 d 50 (96.2) 126 (42.4) 96.2 57.6 2.24 0.08
FEP 26 d 43 (82.7) 162 (54.6) 82.7 45.4 1.51 0.39
Combination of cut-offs
TAZ 16 & TEM 12 b* 39 (75.0) 48 (16.2) 75.0 58.9 4.62 0.08
TCC 15 & TEM 15 d 50 (96.2) 94 (31.7) 96.2 68.3 3.00 0.07
TCC 15 & TEM 15 & IMI 22 d 52 (100) 109 (36.7) 100 63.3 2.70 0.01
TCC 15 & TEM 15 & MER 22 d 52 (100) 110 (37.0) 100 63.0 2.67 0.01
TCC 15 & TEM 15 & IMI 22 & FEP 26 d 52 (100) 92 (31.0) 100 69.0 3.19 0.01
TCC 15 & TEM 15 & MER 22 & FEP 26 d 52 (100) 93 (31.3) 100 68.7 3.16 0.01
Combination of cut-offs + additional tests
TCC 15 & TEM 15 & IMI 22 & IMI 32-Clo d,e 51 (98.1) 81 (27.3) 98.1 72.7 3.55 0.04
TCC 15 & TEM 15 & MER 22 & MER 32-Clo d,e 52 (100) 68 (22.9) 100 77.1 4.31 0.01
TCC 15 & TEM 15 & IMI 22 & FEP 26 d & IMI 32-Clo d,e 51 (98.1) 71 (23.9) 98.1 76.1 4.05 0.04
TCC 15 & TEM 15 & MER 22 & FEP 26d & MER 32-Clod,e 52 (100) 63 (21.2) 100 78.8 4.65 0.01
MER 25 & TEM 11 & Rosco confirm kit c,f 29 (55.8) 23 (9.4) 55.8 90.6 5.82 0.49
MER 27 & TEM 8 & Rosco confirm kit a,g 36 (69.2) 14 (4.7) 69.2 95.3 14.15 0.33
IMI imipenem, MER meropenem, DOR doripenem, FEP cefepime, TAZ piperacillin/tazobactam, TCC ticarcillin/clavulanate, TEM temocillin, Carbase+ or Carbase-
carbapenemase-positive or -negative isolate
areference [13]; b*85 (24.4%) isolates not classified according to reference [14] strategy; creference [15]; dthis study
ecloxacillin test applied only to chromosomally encoding AmpC Enterobacteriaceae
f258 (73.9) of our isolates not tested according to reference [15] because of meropenem diameter ≥25 mm towards these isolates
g 229 (65.6%) of our isolates not tested according to reference [13] because of meropenem diameter ≥27 mm towards these isolates
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(98.1%) was obtained with piperacillin/tazobactam or
ticarcillin/clavulanate clinical breakpoints but with very
low Sp (25.9 and 1.7%, respectively) (Table 2). The use
of cut-offs derived from a previous publication [14] for
piperacillin/tazobactam (<16 mm) or from analysis of
the inhibition zone diameter distribution in the present
study (Additional file 1: Figure S1) for ticarcillin/clavula-
nate (<15 mm) allows increasing significantly Sp, al-
though Sp values remained rather low (<65%). With
regard to temocillin, a high Se, up to 96.2%, was reached
when the previously proposed 12 mm inhibition zone
diameter cut-off [14] or the 15 mm cut-off derived from
our data analysis (Additional file 1: Figure S1) were ap-
plied (Table 2). The use of the previously proposed
8 mm temocillin cut-off [13] decreased the Se to 67.3%
(Table 2).
Screening with a combination of antibiotic disks
The previously published combination [14] of inhibition
zone diameter of piperacillin/tazobactam <16 mm and
temocillin <12 mm yielded a Se of 75.0% but 24.4% of
our isolates were not classified because they did not fit
in any of the categories defined by the authors (Table 2).
Combining ticarcillin/clavulanate <15 mm with temocil-
lin <15 mm as derived from the analysis of zone diame-
ters for our isolates collection increased Se (96.2%) and
Sp (68.3%). Se of 100% and Sp of 63% were reached
when considering an inhibition zone diameter of imipe-
nem or meropenem <22 mm for isolates not retained by
ticarcillin/clavulanate <15 mm and temocillin <15 mm
(Table 2). Finally, the Sp of the latter strategy was signifi-
cantly improved (69 vs 63%, p < 0.001; Table 3) by
retaining only isolates with cefepime inhibition zone
diameter <26 mm for the species producing chromo-
somal AmpC but E. coli (Table 2). All isolates were clas-
sified by using our strategies.
Screening with the classical disc diffusion method and
additional tests
When analysing the results of the different tests ob-
tained on our collection of isolates, the best combination
allowing for reaching a Se of 100% and Sp of 78.8% con-
sisted of the combination of the disk diffusion method
(temocillin <15 mm, ticarcillin/clavulanate <15 mm and,
imipenem or meropenem <22 mm, cefepime <26 mm),
and an additional screening, namely meropenem or imi-
penem <32 mm on MH containing cloxacillin (Table 2
and Fig. 1) for the species producing chromosomal
AmpC but E. coli.
The strategy proposed by van Dijk et al. [15], which
combines temocillin <11 mm and the Rosco confirma-
tory test with regard to isolates selected on meropenem
MIC ≥0.5 mg/L (i.e. estimated inhibition zone diameter
<25 mm) [14], displayed a Se of 55.8% and a Sp of 90.6%
in our collection of isolates (Table 2). It has to be noted
that 73.9% of the isolates of our study, including 20 of
the 52 CPE, would not have been tested because they
displayed a meropenem inhibition zone diameter
Table 3 P-values (McNemar’s test) comparing sensitivities and specificities of selected strategies for the 349 ertapenem non-
susceptible Enterobacteriaceae isolates
TCC ticarcillin/clavulanate, TEM temocillin, MER meropenem, FEP cefepime, TAZ piperacillin/tazobactam, IMI imipenem, Clo Mueller-Hinton agar
containing cloxacillin
atest applied only to Enterobacteriaceae chromosomally encoding Amp-C
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≥25 mm, which is used as first screening criteria by the
authors (Additional file 1: Figure S1).
The strategy proposed by Hrabak et al. [13], which
combines temocillin <8 mm and the Rosco confirmatory
test with regard to isolates selected on meropenem MIC
≥0.25 mg/L (i.e. estimated inhibition zone diameter
<27 mm) [14] displayed a Se of 69.2% and a Sp of 95.3%
in our collection of isolates. However, 65.6% of our iso-
lates, including 12 of the 52 CPE, would not have been
tested because they displayed a meropenem inhibition
zone diameter ≥27 mm, which is used as first screening
criteria by the authors (Additional file 1: Figure S1).
Comparison of screening tests or strategies by using a
likelihood-ratios graph
The overall performances of selected strategies were
plotted on a LR graph (Fig. 2) taking as reference non-
susceptibility to imipenem (<24 mm) because it is a
widely used test. Numerous strategies fell in the B zone,
indicating that they work better than imipenem <24 mm
for eliminating non-CPE isolates.
Doripenem <24 mm fell into the C zone, indicating
that it performs better than the reference for retaining
CPE.
All other strategies fell into the A zone indicating
that they perform better than NS to imipenem alone
for both selecting CPE and eliminating non-CPE iso-
lates. Among all latters, the best characteristics (LR+
and LR-) were for the combinations temocillin
<15 mm + ticarcillin/clavulanate <15 mm +merope-
nem or imipenem <22 mm +meropenem <32 mm on
MH-cloxacillin, and temocillin <15 mm + ticarcillin/
clavulanate <15 mm +meropenem or imipenem
<22 mm and cefepime <26 mm +meropenem
<32 mm on MH-cloxacillin. After full implementa-
tion, the two latter strategies retained a total of 120
(34.4%) or 115 (33.0%) putative CPE isolates for fur-
ther carbapenemase confirmatory tests, respectively.
Hence, the post-strategy CPE proportion reached 43.3
to 45.2% as compared to the 14.9% CPE pre-test
proportion.
Better LR- (i.e. higher specificity) was reached for
temocillin <12 mm + Rosco KPC-MBL confirm kit [15]
and temocillin <8 mm+ Rosco KPC-MBL confirm kit
[13]. When applied on ertapenem NS isolates, these two
strategies allowed for retaining less isolates (n = 50 and
n = 52, respectively) for further testing than our strat-
egies (n = 120 and n = 115) but missed from 16 (30.8%)
to 23 (44.2%) of the 52 CPE.
Applying the most comprehensive strategy, i.e. temo-
cillin <15 mm + ticarcillin/clavulanate <15 mm+mero-
penem or imipenem <22 mm and cefepime <26 mm +
meropenem <32 mm on MH-cloxacillin to our popula-
tion with an initial pre-test probability or CPE preva-
lence of 14.9%, a LR+ value of 4.65 (Table 2) will be
translated into a positive post-test probability or positive
predictive value (PPV) of 45% (Additional file 2:
Table S1), and a LR- value of 0.01 into a negative
post-test probability or negative predictive value
(NPV) close to 100% (Additional file 2: Table S1).
Inoculum size
After our study, EUCAST issued new guidelines for sus-
ceptibility testing, which recommends a larger inoculum
Fig. 1 Proposed strategy to screen carbapenemase-producing Enterobacteriaceae among ertapenem non-susceptible isolates
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size than the CA-SFM recommendations used for our
study [16, 17]. This may question the validity of our
strategies from now on. Hence, we compared inhibition
zone diameters for temocillin and meropenem obtained
by EUCAST and CA-SFM methods on all CPE and a
sample of carbapenemase-negative isolates of our collec-
tion. The correlation between both methods was very
high for both antibiotics and both groups of isolates
(data not shown) and all CPE isolates were classified into
the same groups by both methods when using the cut-
offs of our strategies. Ticarcillin/clavulanate diameters
were not assessed by using EUCAST recommendations,
because all CPE isolates had diameters <15 mm by CA-
SFM method, which implies that diameters will be simi-
lar or smaller with EUCAST larger inoculum size. In
addition, Dortet et al. recently validated our algorithm
by using the larger EUCAST inoculum and testing other
carbapenemase-producing isolates [22].
Discussion
Carbapenemase detection among carbapenem NSE is
a major challenge in the routine laboratory. We de-
signed screening strategies in order to retain 100% of
carbapenemase-positive isolates while reaching the
highest possible specificity by using the disc diffusion
method. To reach our goal, we used data-driven cut-offs of
diameter zones for commonly tested antibiotics including
temocillin, and combined them to design an algorithm.
Our strategies, which have been compared to those pro-
posed by others using a similar approach [13–15], are
shown to be highly relevant when sensitivity is the priority.
Our study and that of Huang et al. [14] are based on a
collection of unselected isolates provided by a large
panel of laboratories throughout the territory. Hence, re-
ported performances are likely to be closed to those ob-
served in the routine laboratory on the opposite to studies
that used either very selected collections of isolates with
sometimes undefined selection criteria or collections de-
rived, for theoretical strategies, from heterogeneous publi-
cations and not tested in the routine laboratory [11, 13].
Our first strategy combining temocillin <15 mm +
ticarcillin/clavulanate <15 mm +meropenem or imipe-
nem <22 mm and cefepime <26 mm, was designed to be
easily implemented in the routine laboratory and to
screen isolates in a single step from the disc diffusion
antibiogram at the same time as carbapenem non-
susceptibility is identified. This strategy confirms the
interest of temocillin combined to other tests in the
screening of CPE [13–15]. However, we used a higher
temocillin cut-off value, which was found to increase
sensitivity. By using cefepime in this strategy, the specifi-
city of the algorithm increased from 63 to 68.7%. Conse-
quently, 58.5% of the total isolates were not retained for
confirmatory tests as compared to 53.6% without cefe-
pime. When validating our algorithm, the French refer-
ence centre for antibiotic resistance did not use
cefepime [22]. Because of the large number of Entero-
bacter spp sent to this reference centre, it is likely that
the use of cefepime would help decreasing the number
of isolates submitted to a confirmatory test. To further
increase the specificity of our algorithm, we used imipe-
nem or meropenem disks on MH containing cloxacillin.
This takes an additional day, similarly to strategies pro-
posed by others who used assays designed to detect carba-
penemase production [13, 15]. Of note, this additional test
allowed for eliminating 67% of the total of carbapenem
NSE. As a result, almost one half (45%) of retained isolates
submitted to confirmatory tests are carbapenemase posi-
tive. By increasing the proportion of CPE among carba-
penem NSE, the positive predictive value of confirmatory
tests will significantly be increased.
Our study has some weaknesses. First, our collection
of isolates does not contain the less frequent
Fig. 2 Comparison of characteristics of single or combined tests
compared to imipenem non-susceptible clinical category (x, imipenem
24) by using likelihood ratio graphs: ● Ticarcillin/clavulanate 24; ○
Ticarcillin/clavulanate 15;▲ Piperacillin/tazobactam 21; Δ Piperacillin/
tazobactam 16; ■ Meropenem 22;▣ Meropenem 25; Meropenem
27; ❏ Doripenem; ◈ Temocillin 8; ♦ Temocillin 12; ◊ Temocillin 15;◣
Cefepime 24; ◥ Cefepime 26; ▼ Temocillin 12 & Piperacillin/
tazobactam 16 [14]; Temocillin 15 & Ticarcillin/clavulanate 15;
⨁ Temocillin 15 & Ticarcillin/clavulanate 15 & Imipenem 22/
Temocillin 15 & Ticarcillin/clavulanate 15 & Meropenem 22; ⨂
Temocillin 15 & Ticarcillin/clavulanate 15 & Imipenem 22 and
Cefepime 26 for AmpC producers/Temocillin 15 & Ticarcillin/clavulanate
15 & Meropenem 22 and Cefepime 26 for AmpC producers;
Temocillin 11 & Rosco KPC-MBL confirm kit [15]; ❖ Temocillin 8
& Rosco KPC-MBL confirm kit [13]; ★□ Temocillin 15 & Ticarcillin/
clavulanate 15 & Meropenem 22 & Meropenem 32 on Mueller-
Hinton-cloxacillin for AmpC producers; ✶ Temocillin 15 & Ticarcillin/
clavulanate 15 & Meropenem 22 and Cefepime 26 & Meropenem
32 on Mueller-Hinton-cloxacillin for AmpC producers
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carbapenemases because isolates were prospectively and
consecutively selected from routine laboratories. For in-
stance, GES type enzymes are lacking, mainly because to
date it has not been identified in France [23]. Neverthe-
less, the designed strategies we are likely to miss such
isolates because ertapenem MIC towards GES-
producing isolates are often lower than the chosen cut-
off (MIC > 0.5 mg/L) [8, 24]. Similarly, for a few OXA-
48-producing Enterobacteriaceae and notably K. pneu-
moniae, ertapenem MIC is ≤0.5 mg/L. Second, we chose
to analyse a randomly selected sample of all
carbapenem-NS E. cloacae collected during the study-
period. Among those isolates, none was found to pro-
duce carbapenemase, and we were not able to challenge
our screening strategies against carbapenemase-positive
E. cloacae. However, the recent study of Dortet et al.
proved that our algorithm applied in a reference centre
did not miss any of the 19 carbapenemase-producing
Enterobacter spp among the 214 Enterobacter spp iso-
lates tested [22]. Third, the study was performed by vol-
untary laboratories, that, although rather numerous, may
not be representative of all French laboratories. Finally,
it should be noticed that since we performed our study,
new or updated commercialized versions of carbapenem
hydrolysis assays have been issued and should be further
tested against our strategies [25, 26].
Conclusions
In conclusion, our study proposes strategies to screen
candidates for being CPE among a large panel of
carbapenem-NS isolates. The advantages of these
screening strategies are to reach 100% sensitivity by
keeping a rather satisfactory specificity and to be applied
in the routine laboratories directly from the disk diffu-
sion method. The strategies should be considered as a
tool for selecting isolates that will be further tested with
more refined techniques such as PCR-based assays or
assays based on the carbapenemase activity detection.
For the latter, the advent of newer and cheaper versions
of these assays should facilitate their use in most labora-
tories, mainly after screening. The proposed strategies
will also help decreasing unnecessary implementation of
isolation precautions in the hospital setting.
Additional files
Additional file 1: Figure S1. Distribution of inhibition zone diameters
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temocillin (D), imipenem (E), and meropenem (F). (JPG 87 kb)
Additional file 2: Table S1. Formulas to calculate post-test probabilities
with positive and negative likelihood ratios (LR+ and LR−). (DOCX 11 kb)
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